Details checkedClinical trial listing onlyCheckedtrial

TJ0113 Capsules by Hangzhou PhecdaMed

Also known as: TJ0113, TJ0113 capsules

Hangzhou PhecdaMed Co., Ltd.

Primary source

Company

Hangzhou PhecdaMed Co., Ltd.

Program Type

Therapeutic

Modality

Small Molecule

Stage

Interventional/NA

Status

Active

Target Gene

—

Route / Mode

Oral capsule

Confidence

78%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

China

Population

adult, older-adult, age-related

Trial IDs

Mechanism

Oral investigational small molecule being evaluated in a randomized placebo-controlled study for age-related hearing loss; public mechanism details were not confirmed in this pass.

Indications

Hearing Loss Sensorineural Hearing Loss Age-Related Hearing Loss

Notes

Verified as a registry-backed active interventional age-related hearing-loss study. The phase and mechanism remain under-disclosed in public sources reviewed here, so it stays Tier 3 despite being a direct hearing-loss therapeutic candidate.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, company, allCompanies, stage, status, route, indications, populationTags...

IDs: NCT07012746, TJ0113

Open

Key Events

2025-06-02

ClinicalTrials.gov posted TJ0113 randomized placebo-controlled age-related hearing-loss study

Clinical Trials (1)

NCT07012746

Data Checks